Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction STAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the...

Sema4 to Participate at Three Upcoming Investor Conferences in November STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021 STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...

Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer STAMFORD, Conn., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the appointment of Gustavo Stolovitzky, PhD, to the...

Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health STAMFORD, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sema4, an AI-driven genomic and clinical data intelligence platform company, today announced the launch of Sema4 Elements™, a portfolio of...